Markets:

Overview

News

Currencies

International

Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

17.37 +0.52 (+3.09%)

Streaming Delayed Price Updated: 1:37 PM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 02, 2024

Via Benzinga

Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates ↗

December 02, 2024

Via Benzinga

Topics Stocks

XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗

December 02, 2024

Via Benzinga

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients ↗

December 02, 2024

NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients.

Via Benzinga

Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds ↗

December 02, 2024

The company is soon to seek regulatory approval in the U.S. and abroad.

Via Investor's Business Daily

Navigating 5 Analyst Ratings For NovoCure ↗

December 02, 2024

Via Benzinga

Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings) ↗

October 16, 2024

Via Benzinga

Why NovoCure Stock Dived by 13% This Week ↗

September 06, 2024

Investors found the announced changes to the company's C-suite unsettling.

Via The Motley Fool

This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

December 02, 2024

Via Benzinga

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

December 02, 2024

From Zai Lab

Via Business Wire

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

December 02, 2024

From Novocure

Via Business Wire

Novocure to Participate in Upcoming Investor Conferences

November 27, 2024

From Novocure

Via Business Wire

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

November 21, 2024

From Novocure

Via Business Wire

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

November 21, 2024

From Novocure

Via Business Wire

NovoCure (NVCR) Q3 2024 Earnings Call Transcript ↗

October 30, 2024

NVCR earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Novocure Appoints Christoph Brackmann as Chief Financial Officer

October 30, 2024

From Novocure

Via Business Wire

Novocure Reports Third Quarter 2024 Financial Results

October 30, 2024

From Novocure

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 16, 2024

Via Benzinga

US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips ↗

October 16, 2024

U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session.

Via Benzinga

Topics Stocks

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients ↗

October 16, 2024

NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non-small cell lung cancer patients, demonstrating significant...

Via Benzinga

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment ↗

October 15, 2024

The company could have a long path ahead to reimbursement and, ultimately, sales.

Via Investor's Business Daily

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

October 15, 2024

From Novocure

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 07, 2024

Via Benzinga

Novocure to Report Third Quarter 2024 Financial Results

October 01, 2024

From Novocure

Via Business Wire

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

September 09, 2024

From Novocure

Via Business Wire

Novocure Announces Planned CEO Transition

September 03, 2024

From Novocure

Via Business Wire

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

August 28, 2024

From Novocure

Via Business Wire

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 03, 2024

Via Benzinga

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

August 14, 2024

From Novocure

Via Business Wire

Chips, Glorious Chips! ↗

August 07, 2024

Someone's gotta make 'em, and someone's gotta buy 'em.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.